{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:23:34Z","timestamp":1791779014037,"version":"4.3.4"},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/mph.0b013e3181e6f003","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T06:22:14Z","timestamp":1282198934000},"page":"554-563","source":"Crossref","is-referenced-by-count":106,"title":["Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"32","author":[{"given":"Elizabeth A.","family":"Raetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda L.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210227","first-page":"942","article-title":"L-asparaginase in the treatment of neoplastic diseases in children","volume":"31","author":"Jaffe","year":"1971","journal-title":"Cancer Res"},{"key":"R2-7-20210227","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","article-title":"L-asparaginase: clinical, biochemical, pharmacological, and immunological studies","volume":"74","author":"Capizzi","year":"1971","journal-title":"Ann Intern Med"},{"key":"R3-7-20210227","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM198609113151101","article-title":"Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia","volume":"315","author":"Clavell","year":"1986","journal-title":"N Engl J Med"},{"key":"R4-7-20210227","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mpo.2950030410","article-title":"Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia","volume":"3","author":"Jones","year":"1977","journal-title":"Med Pediatr Oncol"},{"key":"R5-7-20210227","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-7-20210227","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"R7-7-20210227","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H","article-title":"E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children","volume":"25","author":"Tallal","year":"1970","journal-title":"Cancer"},{"key":"R8-7-20210227","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Res"},{"key":"R9-7-20210227","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"R10-7-20210227","first-page":"101","article-title":"L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group","volume":"65","author":"Nesbit","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"R11-7-20210227","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/1097-0142(1971)28:4<819::AID-CNCR2820280403>3.0.CO;2-9","article-title":"L-asparaginase therapy in children with advanced leukemia: The Southwest cancer chemotherapy study group","volume":"28","author":"Sutow","year":"1971","journal-title":"Cancer"},{"key":"R12-7-20210227","first-page":"466","article-title":"L-Asparagine Requirement and the effect of L-Asparaginase on the normal and leukemic human bone marrow","volume":"30","author":"Ho","year":"1970","journal-title":"Cancer Res"},{"key":"R13-7-20210227","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.127.6.1055","article-title":"Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: Differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells","volume":"127","author":"Broome","year":"1968","journal-title":"J Exp Med"},{"key":"R14-7-20210227","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3570321","article-title":"Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells","volume":"357","author":"Aslanian","year":"2001","journal-title":"Biochem J"},{"key":"R15-7-20210227","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","article-title":"L-asparaginase resistance in human leukemia\u2013asparagine synthetase","volume":"18","author":"Haskell","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"R16-7-20210227","doi-asserted-by":"crossref","first-page":"C1691","DOI":"10.1152\/ajpcell.1997.272.5.C1691","article-title":"Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells","volume":"272","author":"Hutson","year":"1997","journal-title":"Am J Physiol"},{"key":"R17-7-20210227","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J Clin Invest"},{"key":"R18-7-20210227","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood-2005-06-2597","article-title":"Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia","volume":"107","author":"Appel","year":"2006","journal-title":"Blood"},{"key":"R19-7-20210227","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2004-10-3892","article-title":"Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia","volume":"105","author":"Stams","year":"2005","journal-title":"Blood"},{"key":"R20-7-20210227","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"R21-7-20210227","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"R22-7-20210227","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokinetic"},{"key":"R23-7-20210227","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/clpt.2009.162","article-title":"Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia","volume":"86","author":"Panetta","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R24-7-20210227","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1097-0142(197208)30:2<339::AID-CNCR2820300206>3.0.CO;2-P","article-title":"Toxicity of L-asparginase in children with advanced leukemia","volume":"30","author":"Land","year":"1972","journal-title":"Cancer"},{"key":"R25-7-20210227","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"R26-7-20210227","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.03148.x","article-title":"Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system","volume":"115","author":"Albertsen","year":"2001","journal-title":"Br J Haematol"},{"key":"R27-7-20210227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MPH.0b013e318047b79d","article-title":"Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients","volume":"29","author":"Avramis","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"R28-7-20210227","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"R29-7-20210227","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.1999.01192.x","article-title":"Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL\/NHL-BFM treatment protocols","volume":"104","author":"Vieira Pinheiro","year":"1999","journal-title":"Br J Haematol"},{"key":"R30-7-20210227","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2000.02187.x","article-title":"Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols","volume":"110","author":"Muller","year":"2000","journal-title":"Br J Haematol"},{"key":"R31-7-20210227","first-page":"6568","article-title":"Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor","volume":"51","author":"Asselin","year":"1991","journal-title":"Cancer Res"},{"key":"R32-7-20210227","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/oxfordjournals.annonc.a010722","article-title":"L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase","volume":"7","author":"Gentili","year":"1996","journal-title":"Ann Oncol"},{"key":"R33-7-20210227","first-page":"299","article-title":"Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL)","volume":"29","author":"Avramis","year":"2009","journal-title":"Anticancer Res"},{"key":"R34-7-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-008-0026-9","article-title":"The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations","volume":"9","author":"Zalewska-Szewczyk","year":"2009","journal-title":"Clin Exp Med"},{"key":"R35-7-20210227","first-page":"1878","article-title":"Assessment of anti-asparaginase (ASNase) antibodies (Ab) and ASNase activity after suspected clinical allergy","volume":"108","author":"Tiwari","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"R36-7-20210227","first-page":"335","article-title":"Adverse reactions of L-asparaginase","volume":"4","author":"Cairo","year":"1982","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R37-7-20210227","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1097-0142(19820401)49:7<1378::AID-CNCR2820490713>3.0.CO;2-Z","article-title":"Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma","volume":"49","author":"Evans","year":"1982","journal-title":"Cancer"},{"key":"R38-7-20210227","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/10428190701292049","article-title":"The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia","volume":"48","author":"Zalewska-Szewczyk","year":"2007","journal-title":"Leukemia Lymphoma"},{"key":"R39-7-20210227","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1365-2141.2001.03009.x","article-title":"Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment","volume":"114","author":"Muller","year":"2001","journal-title":"Br J Haematol"},{"key":"R40-7-20210227","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"R41-7-20210227","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"R42-7-20210227","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPH.0b013e3181483df1","article-title":"Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study","volume":"29","author":"Wacker","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"R43-7-20210227","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R44-7-20210227","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"R45-7-20210227","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.leu.2401007","article-title":"Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia","volume":"12","author":"Larson","year":"1998","journal-title":"Leukemia"},{"key":"R46-7-20210227","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia","volume":"1","author":"Nesbit","year":"1979","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R47-7-20210227","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"R48-7-20210227","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-001-0391-5","article-title":"PEG-asparaginase (Oncaspar) 2500\u2009U\/m(2) BSA in reinduction and relapse treatment in the ALL\/NHL-BFM protocols","volume":"49","author":"Muller","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R49-7-20210227","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pbc.20406","article-title":"Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2500\u2009IU\/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97","volume":"46","author":"Vieira Pinheiro","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R50-7-20210227","first-page":"1854","article-title":"Intravenous PEG asparaginase during remission induction for childhood ALL","volume":"108","author":"Silverman","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"R51-7-20210227","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R52-7-20210227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R53-7-20210227","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/1097-0142(197403)33:3<611::AID-CNCR2820330303>3.0.CO;2-U","article-title":"Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase","volume":"33","author":"King","year":"1974","journal-title":"Cancer"},{"key":"R54-7-20210227","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M","article-title":"Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to E Coli. asparaginase","volume":"70","author":"Billett","year":"1992","journal-title":"Cancer"},{"key":"R55-7-20210227","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/1097-0142(197208)30:2<376::AID-CNCR2820300212>3.0.CO;2-4","article-title":"Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli","volume":"30","author":"Ohnuma","year":"1972","journal-title":"Cancer"},{"key":"R56-7-20210227","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"R57-7-20210227","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00043426-200405000-00001","article-title":"Optimal asparaginase therapy","volume":"26","author":"Holcenberg","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R58-7-20210227","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","article-title":"Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia","volume":"12","author":"Woo","year":"1998","journal-title":"Leukemia"},{"key":"R59-7-20210227","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","article-title":"Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia","volume":"37","author":"Killander","year":"1976","journal-title":"Cancer"},{"key":"R60-7-20210227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","article-title":"Toxicity of E. coli L-asparaginase in man","volume":"25","author":"Oettgen","year":"1970","journal-title":"Cancer"},{"key":"R61-7-20210227","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MPH.0b013e3180640d54","article-title":"Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"29","author":"Salzer","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"R62-7-20210227","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"},{"key":"R63-7-20210227","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"R64-7-20210227","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"R65-7-20210227","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber cancer institute acute lymphoblastic leukemia consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"key":"R66-7-20210227","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/08880019809018315","article-title":"L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia","volume":"15","author":"Sahu","year":"1998","journal-title":"Pediatr Hematol Oncol"},{"key":"R67-7-20210227","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T","article-title":"Pegaspargase-induced pancreatitis","volume":"34","author":"Alvarez","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"R68-7-20210227","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1097-0142(197409)34:3<780::AID-CNCR2820340338>3.0.CO;2-U","article-title":"Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy","volume":"34","author":"Weetman","year":"1974","journal-title":"Cancer"},{"key":"R69-7-20210227","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/pbc.21721","article-title":"Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia","volume":"51","author":"Wu","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R70-7-20210227","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1096-911X(199802)30:2<106::AID-MPO7>3.0.CO;2-M","article-title":"Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis","volume":"30","author":"Garrington","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"R71-7-20210227","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/pbc.21037","article-title":"Predicting asparaginase-associated pancreatitis","volume":"49","author":"Knoderer","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R72-7-20210227","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"key":"R73-7-20210227","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R74-7-20210227","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pbc.21734","article-title":"Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer","volume":"51","author":"Athale","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R75-7-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2003.10.013","article-title":"Thrombosis in children with acute lymphoblastic leukemia: Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"key":"R76-7-20210227","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"key":"R77-7-20210227","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0049-3848(01)00286-9","article-title":"Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant escherichia coli asparaginase\/prednisone administration","volume":"103","author":"Nowak-G\u00f6ttl","year":"2001","journal-title":"Thromb Res"},{"key":"R78-7-20210227","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1160\/TH07-10-0620","article-title":"L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia","volume":"100","author":"Appel","year":"2008","journal-title":"Thromb Haemost"},{"key":"R79-7-20210227","first-page":"2297","article-title":"Biochemical and pharmacological studies with asparaginase in man","volume":"30","author":"Ohnuma","year":"1970","journal-title":"Cancer Res"},{"key":"R80-7-20210227","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.38.1.127","article-title":"Cerebrovascular complications of L-asparaginase therapy","volume":"38","author":"Feinberg","year":"1988","journal-title":"Neurology"},{"key":"R81-7-20210227","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00043426-200306000-00011","article-title":"Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia","volume":"25","author":"Kieslich","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R82-7-20210227","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0022-3476(78)81075-0","article-title":"Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors","volume":"93","author":"Carpentieri","year":"1978","journal-title":"J Pediatr"},{"key":"R83-7-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00422255","article-title":"The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man","volume":"15","author":"Lavine","year":"1978","journal-title":"Diabetologia"},{"key":"R84-7-20210227","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/000992288302200507","article-title":"Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia","volume":"22","author":"Turner","year":"1983","journal-title":"Clin Pediatr"},{"key":"R85-7-20210227","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3476(81)80955-9","article-title":"Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone","volume":"99","author":"Pui","year":"1981","journal-title":"J Pediatr"},{"key":"R86-7-20210227","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/pbc.21505","article-title":"Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia","volume":"50","author":"Roberson","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R87-7-20210227","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3476(70)80023-3","article-title":"Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia","volume":"77","author":"Pratt","year":"1970","journal-title":"J Pediatr"},{"key":"R88-7-20210227","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1097-0142(197108)28:2<361::AID-CNCR2820280215>3.0.CO;2-3","article-title":"Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy","volume":"28","author":"Pratt","year":"1971","journal-title":"Cancer"},{"key":"R89-7-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1445-5994.1971.tb02253.x","article-title":"L-asparaginase\u2013clinical experience in leukaemia, lymphoma and carcinoma","volume":"1","author":"Biggs","year":"1971","journal-title":"Austral N Z J Med"},{"key":"R90-7-20210227","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2003-42647","article-title":"Histopathological features of L-asparaginase-induced liver disease","volume":"23","author":"Sahoo","year":"2003","journal-title":"Sem Liv Dis"},{"key":"R91-7-20210227","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000095827","article-title":"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase","volume":"74","author":"Bodmer","year":"2006","journal-title":"Digestion"},{"key":"R92-7-20210227","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Blood"},{"key":"R93-7-20210227","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.leu.2401886","article-title":"Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study","volume":"14","author":"Harris","year":"2000","journal-title":"Leukemia"},{"key":"R94-7-20210227","first-page":"1680","article-title":"L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins","volume":"9","author":"Pui","year":"1995","journal-title":"Leukemia"},{"key":"R95-7-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary leukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R96-7-20210227","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00008571-200211000-00004","article-title":"Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies","volume":"12","author":"Blanco","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R97-7-20210227","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: I. properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"Broome","year":"1963","journal-title":"J Exp Med"},{"key":"R98-7-20210227","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1097-0142(196612)19:12<1813::AID-CNCR2820191208>3.0.CO;2-E","article-title":"Toxic and antineoplastic effects of l-asparaginase: study of mice with lymphoma and normal monkeys and report on a child with leukemia","volume":"19","author":"Dolowy","year":"1966","journal-title":"Cancer"},{"key":"R99-7-20210227","first-page":"535","article-title":"L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res"},{"key":"R100-7-20210227","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.1998.16.8.2840","article-title":"Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study","volume":"16","author":"Harris","year":"1998","journal-title":"J Clin Oncol"},{"key":"R101-7-20210227","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Res"},{"key":"R102-7-20210227","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2401980","article-title":"Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981\u20131995)","volume":"14","author":"Silverman","year":"2000","journal-title":"Leukemia"},{"key":"R103-7-20210227","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"R104-7-20210227","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.2001.19.5.1297","article-title":"Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study\u2013a report from the Associazione Italiana Ematologia Oncologia Pediatrica","volume":"19","author":"Rizzari","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e3181e6f003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:38:40Z","timestamp":1786041520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201010000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3181e6f003","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}